A panel of kinases whose inhibition increased apoptosis of pancreatic adenocarcinoma cells in vitro was recently established. The aim of this work was to observe in a mouse xenograft model whether inhibition of these kinases would alter pancreatic tumor growth. Rate of apoptosis, caspase-3 activity and cell viability were assessed in two pancreatic cancer cell lines, MiaPaCa2 and BxPC3, after inhibiting selected kinases by transfection of specific siRNAs. For in vivo experiments, MiaPaCa2 cells were injected into the pancreas of nude mice, where they formed tumors. Inhibition of kinases was obtained by repeated intraperitoneal (i.p.) injections of modified O-Methyl (OMe) siRNAs specific for the selected kinases. Tumor volumes were assessed after 21 days. Among selected kinases, PAK7, MAP3K7 and CK2a were those whose inhibition increased apoptosis the most in vitro. Simultaneous inhibition of two of them increased apoptosis up to five times. Moreover, inhibiting these kinases had little effect on 10 non-pancreatic cell lines, suggesting pancreatic specificity. In vivo, OMe-siRNAs induced significant but incomplete inhibition of kinase expression (45-75%). Nevertheless, such inhibition resulted in a twofold increase in caspase-3 activity in tumors and a strong reduction in tumor volume (about 75%). In vivo inhibition by OMe-siRNAs of three survival kinases apparently specific for pancreatic cancer cells, PAK7, MAP3K7 and CK2a, decreases significantly the growth of xenografted MiaPaCa2 cells. This strategy is therefore of potential clinical interest.
Introduction
In spite of many efforts, the past decades have seen little progress in the treatment of pancreatic adenocarcinoma. 1 The 5-year survival rate remains under 5%, except for patients whose cancer is diagnosed early enough to allow surgical resection, for whom it can increase to 20%. However, they represent only 10-20% of the patients. Classical chemotherapeutic agents that are efficient in other cancers have no effect in the pancreas. The cytosine analog gemcitabine is the only molecule that provides some survival benefit to patients with advanced stage of the disease, 2 but improvement is limited, and attempts to increase gemcitabine efficacy by modulating pharmacokinetic parameters or by using the drug in combination with conventional cytotoxic drugs such as oxaliplatin failed. 3, 4 More recently, new drugs such as inhibitors of farnesyltransferase, matrix metalloproteases, cyclooxygenase-2 and lipoxygenase have entered clinical trials but, unfortunately, the first evaluations are not encouraging. 5 The failure of the present anti-cancer strategies means that new directions should be explored. One possibility would be to target the mechanisms by which cancer cells escape apoptosis. Kinases control the reversible process of phosphorylation and are deregulated in many diseases, such as cancer. As protein and lipid phosphorylations control cell survival signaling, strategies targeting kinases are very good candidates as new, more efficient therapies. The currently available kinase inhibitors are effective treatments for some cancers. For example, drugs such as imatinib and gefitinib inhibit tumor growth by antagonizing specific survival kinases, thus reversing the malignant phenotype of chronic myeloid leukemia and non-small-cell lung cancer. Unfortunately, most tumors are heterogeneous and poorly characterized, making it difficult to treat them efficiently with a single agent, and combination therapies targeting multiple signaling pathways are now privileged. The description of the complete human kinome 6 allowed us to establish, in vitro, a catalog of pancreatic cancer cell survival kinases. 7 More recently, modified siRNAs allowing inhibition of specific genes in vivo have become available. Using this tool, we could assess the influence of combined inhibition of survival kinases in vivo in a mouse xenograft model of pancreatic adenocarcinoma.
Materials and methods
Cell lines and cell culture conditions MiaPaCa-2, MCF7, SaOS-2, A375, SW872, MDA-MB231, LS174T and U2OS cell lines were grown in Dulbecco's modified Eagle's medium (DMEM) supplemented with 10% fetal bovine serum, 2 mM L-glutamine, 100 IU ml -1 penicillin G and 100 mg ml -1 streptomycin. BxPC3, HRT18, H1299 and H358 cells were cultivated in RPMI 1640 medium in the presence of 2 mM L-glutamine, 4.5 g l -1 glucose, 10 mM Hepes, 1 mM sodium pyruvate, 10% fetal bovine serum, and 100 IU ml -1 penicillin G and 100 mg ml -1 streptomycin. All cell lines were routinely cultivated in humidified 5% CO 2 atmosphere.
siRNA design
The siRNAs used in this study were designed by Qiagen, Courtaboeuf, France. The sequences are PAK7 siRNA (sense 5
. siRNAs with O-Methyl (OMe)-modified nucleotides were used for in vivo experiments using this pattern (sense 5 0 -OMeX-OMeX-OMeX-OMeX-OMeX-XXXXX XXX-OMeX-OMeX-OMeX-OMeX-OMeX-d(TT)-3 0 ).
Transfection
Cells were seeded for 24 h in 96-well, 48-well and 6-well plates 40 (40 000 cells per cm   2 ). Unmodified siRNAs were transfected in cells with a mixture of 50 nM siRNA and X-tremeGENE siRNA Transfection Reagent (Roche, Neuilly, France). OMe-siRNAs were used at a concentration of 50 nM using JetPEI Transfection Reagent (Polyplus, Illkirch, France). Non-silencing unmodified or OMe-siRNA was used as negative control.
Apoptosis assay
Two days after siRNA transfection in 96-well plates, apoptosis was assessed by an ELISA that quantifies cytoplasmic nucleosomes produced during apoptosis (Cell Death Detection ELISA plus, Roche). The 96-well plates were centrifuged (200 g) for 10 min, the supernatant was discarded and lysis buffer was added. After lysis, the samples were centrifuged and 20 ml of the supernatant was transferred to a streptavidin-coated microtitration plate. Biotin-labeled anti-histone antibodies and peroxidaseconjugated anti-DNA antibodies were added to each well, and the plate was incubated at room temperature for 2 h. After three washes with buffer, the peroxidase substrate was added to each well to quantitate the captured nucleosomes. After a 5-min incubation, the plates were read at 405 nm in a microplate reader. The enrichment in histone-DNA fragments is expressed as fold increase in absorbance as compared with control (non-silencing) siRNA. Experiments were carried out in triplicate and repeated three times.
Flow cytometry
Cells were washed with phosphate-buffered saline (PBS) and fixed in cold ethanol 70% for 30 min at 4 1C. After a wash with PBS, cells were treated with 50 ml RNAse A (100 mg ml -1 ), labeled with 200 ml propidium iodide (20 mg ml -1 ) and immediately analyzed by flow cytometry (FACSCalibur, Becton Dickinson, Franklin-Lakes, NJ). Cell death analysis was carried out on 30 000 cells, evaluating the sub-G1 ratio (FlowJo, Ashland, OR). The experiments were repeated at least three times and each sample was assayed in triplicate.
Viability assay
Two days after siRNA transfection in 96-well plates, 10 ml of the MTS reagent mixture (3-4,5-dimethylthiazol-2-yl)-5-3-carboxymethoxyphenyl)-2-4-sulfophenyl)-2H-tetrazolium) obtained from Promega, Madison, WI was added per well, the plates were incubated at 37 1C for 45 min, and the absorbance at 490 nm was monitored. The percentage of viable cells in a well was obtained from the ratio of absorbances of cells transfected with kinase siRNAs to cells transfected with control siRNA.
Caspase-3 activity Caspase-3 activity was measured using the Apo-ONE Homogeneous Caspase-3 Assay Fluorometric Kit (Promega). Two days after siRNA transfection in 48-well plates, caspase-3 activity was measured by cleavage of the fluorogenic substrate Z-DEVD-R110 according to the manufacturer's (Promega) instructions.
Semiquantitative RT-PCR analysis Total RNA was extracted using Trizol (Invitrogen, Carlsbad, CA, USA) following the manufacturer's description. RNAs (1 mg) were analyzed by RT-PCR with the Promega One-
Step RT-PCR system. RT-PCR was carried out using various numbers of cycles to verify that the conditions chosen were within the linear range. 
In vivo experiments
Six-week-old male Swiss Nude mice were anesthetized by i.p. injection of a ketamine-xylazine mix (100 mg kg -1
10 mg kg -1 ) and the abdomen was opened through a midline incision. MiaPaCa2 cells (10 7 cells in 200 ml PBS) were injected directly into the pancreas. This procedure is known to generate intrapancreatic xenografts within 21 days. 8 The next day, 30 mg OMe-siRNAs þ and 25 ml JetPEI 4 Â were incubated in 160 ml JetPEI buffer (10 mM HEPES-150 mM NaCl, pH 7.4) for 1 h and injected i.p. The siRNA injection was repeated every third day (seven injections in total). Animals were weighed before each injection. Twenty days after injection of the cells, the animals were killed and the presence of intrapancreatic tumors was assessed. Dimensions of pancreatic tumors were measured with a caliper and tumor volume was calculated as (4p/3) Â (width/2) 2 Â (length/2).
Immunohistochemistry of active caspase-3
Tissues were formalin-fixed and paraffin-embedded. After deparaffinization and blocking of nonspecific binding, sections were incubated with an anti-human active-caspase-3 antibody (1:200; Promega). The immunoperoxidase procedure was carried out using a Vectastain goat anti-rabbit kit (Vector Laboratories, Burlingame, CA). The active caspase-3-labeled surface was quantified with an Olympus BX61 automated microscope ( Â 10 objective), using a Samba 2050 image analyzer (Samba Technologies, Meylan, France).
Statistical analysis
Results shown represent means ± s.d. Statistical analysis was performed with Student's t-test and ANOVA tests.
Results
Combined inhibition of PAK7, MAP3K7 and CK2a survival kinases increases apoptosis of pancreatic cancer cells in vitro We have shown earlier that simultaneous inhibition of two or three pancreatic cancer survival kinases could have a stronger effect on apoptosis than a single inhibition. As a follow-up to this work and to look for the most efficient combination, we chose in the recently published catalog of 56 pancreatic cancer survival kinases 7 the 10 kinases whose inhibition showed the highest activity on apoptosis and monitored the effect of their combined inhibition. These kinases are the following (name and access number): PAK7 (p21(CDKN1A)-activated kinase 7, NM_177990); CK2a (casein kinase 2, a 1 polypeptide, NM_177560); AK1 (adenylate kinase 1, NM_000476); GRAF (GTPase regulator associated with focal adhesion kinase pp125(FAK), NM_015071); MAP3K (mitogenactivated protein kinase kinase kinase 7, NM_003188); DCK (deoxycytidine kinase, NM_000788); DGKH (diacylglycerol kinase Z, NM_178009); TNNI3K (TNNI3 interacting kinase, NM_015978); PRPF4B (PRP4 pre-mRNA processing factor 4 homolog B (yeast), NM_176800); TPK1 (thiamin pyrophosphokinase 1, NM_022445).
MiaPaCa2 cells were transfected with dual combinations of survival kinase-specific siRNAs. Two days after transfection, apoptosis was measured. Combinations of MAP3K7/CK2a, PAK7/CK2a and PAK7/ MAP3K7 showed the highest induction of apoptosis (3.55, 3.48 and 3.42-fold, respectively) ( Figure 1 ). These three survival kinases were chosen for subsequent experiments.
To confirm earlier results showing that simultaneous inhibition of two kinases might improve apoptosis induction, MiaPaCa2 and BxPC3 cell lines were transfected with siRNAs for the selected kinases, alone or in dual or triple combinations, and apoptosis was monitored 2 days later ( Figure 2 ). Single inhibitions resulted in significant increases in apoptosis, as evidenced by cytoplasmic nucleosome assay, in both cell lines. For example, inhibition of CK2a in MiaPaCa-2 increased the apoptosis 2.5-fold and inhibition of MAP3K7 in BxPC3 increased the apoptosis 4-fold. Simultaneous inhibition of two or three kinases resulted in further increase, reaching fivefold induction of apoptosis in MiaPaCa2 cells and sixfold in BxPC3 (Figure 2a) . As a control, apoptosis was also assessed by flow cytometry in MiaPaCa2 cells. In cells transfected with control siRNA, the sub-G 1 fraction represented about 8% of the cells and increased upon transfection with survival kinase siRNAs, reaching a maximum of 29% for the PAK7/MAP3K7 combination (Figure 2b) .
The influence of kinase inhibition on cell viability was also assessed. Viability was significantly altered by kinase Combining kinase inhibitors in pancreatic cancer V Giroux et al inhibition. BxPC3 cells were apparently more sensitive than MiaPaCa2 cells as inhibition with any of the three single kinases resulted in diminution by half of the viability, with no further effect of multiple inhibitions. In MiaPaCa2 cells, however, single inhibitions had more moderate effects. Dual inhibitions were apparently more efficient than single inhibitions, but this was not confirmed by statistical analysis. Finally, no improvement was observed when all three kinases were inhibited (Figure 2c ).
To assess specificity of the selected kinases for pancreatic cancer cells, caspase-3 activity and cell viability were assessed in MiaPaCa2 cells and in 10 non-pancreatic cancer cells after PAK7, MAP3K7 and CK2a siRNA transfections ( Figure 3) . In MiaPaCa2 cells, caspase-3 activity was strongly induced after siRNA transfection (3.4, 3.3 and 3.7 for PAK7, MAP3K7 and CK2a siRNAs, respectively), whereas cell viability was strongly decreased (by 36, 35 and 39% for PAK7, MAP3K7 and CK2a siRNAs, respectively). None of the other cell lines showed significant increase of caspase-3 activity after inhibition of the three kinases. The only significant increases were observed in MDA-MB 231 cells after inhibition of MAP3K7 and CK2 and in HRT18 cells transfected with PAK7 or CK2 siRNA. After transfection with the three siRNAs, cell viability was decreased by 30-40% in MiaPaCa2 cells but remained unchanged in all other cell lines, except for MCF7, in which a 20% decrease was observed.
O-Me-modified siRNAs (OMe-siRNAs) of survival kinases inhibit efficiently mRNA expression in vitro and induce apoptosis The aim of this work was to observe whether inhibition of specific kinases would affect pancreatic cancer progression in a mouse xenograft model. As no chemical inhibitor was available for some of the kinases selected earlier in vitro, we decided to inhibit the kinases in vivo with the siRNA strategy, which proved successful in vitro. However, siRNA approaches in vivo require that (i) the siRNAs remain reasonably functional in an environment that contains nucleases and (ii) intact siRNAs be efficiently delivered to the target cells. Native siRNAs are rapidly degraded, and mammalian cells do not readily take up naked nucleic acids. We opted for chemically modified siRNAs in which the five first bases in 3 0 and 5 0 were 2 0 -O-methylated. These modifications are supposed to increase siRNA resistance to nucleases while maintaining their activity. 9 As a vector to target the siRNAs to pancreatic cancer cells, we used jet-PEI, a polyethylenimine mixture of undisclosed composition, supposed to allow very efficient transfection in vivo. 10 This strategy had to be validated in vitro before working in vivo.
MiaPaCa2 cells were transfected with PAK7, MAP3K7 and CK2a OMe-siRNAs, each combined with JetPEI. Two days after transfection, mRNA expression was assayed by semiquantitative RT-PCR (Figure 4a ) and quantitative RT-PCR (Figure 4b ). The expressions of the three kinases were indeed strongly decreased in cells Figure 1 Induction of apoptosis in MiaPaCa2 cells after inhibition of couples of selected kinases. The 10 kinases are those whose single inhibition is most efficient at promoting apoptosis. Inhibition was obtained by transfecting the cells with specific siRNAs as described in Materials and methods. Apoptosis is given as fold increase respective to control (transfection with scrambled siRNAs). Results represent mean±s.e. for three independent experiments. Black columns refer to couples whose inhibition generates the highest apoptosis.
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V Giroux et al transfected with their specific OMe-siRNAs (65-85% decrease of mRNA expression). We also tested whether the O-Me-siRNAs of PAK7, MAP3K7 and CK2a could induce apoptosis in MiaPaCa2 cells to the same extent as their naked counterparts. Apoptosis was monitored 48 h after transfection with PAK7, MAP3K7 and CK2a specific OMe-siRNAs mixed with JetPEI and was found to be induced 2-, 2.2-and 1.8-fold, respectively (Figure 4c ), about half the values observed with naked siRNAs. Caspase-3 activity was increased about 2-fold (Figure 4d ), again half the value recorded with the naked siRNAs. However, similar to naked siRNAs, cell viability was found decreased by about 50%, as compared with control ( Figure 4e ). It was concluded that OMe-modifications of siRNAs decreased their efficacy on kinase expressions while keeping their effect on cell survival, and could be used in vivo in our xenograft model.
Inhibition of survival kinases in vivo with
OMe-siRNAs/ JetPEI complexes reduces the size of tumors in nude mice with pancreatic xenografts Nude mice were injected with 10 7 MiaPaCa2 cells in the pancreas in order to develop xenografts. Then, groups of 10 mice were randomly treated with combinations of one, two or three OMe-siRNAs specific for PAK7, MAP3K7, CK2a survival kinases, in a complex with JetPEI, according to the schedule described in Materials and methods. Their weight was monitored during the study and no difference was observed between groups (not shown), suggesting limited toxicity of siRNA administration in vivo, if any. Twenty days after cell injection, mice were killed, tumors were removed and their volume was measured. The mean volume for control mice was 0.90 ± 0.12 cm 3 ( Figure 5 ). Volumes after administration of single siRNAs were 0.51±0.14, 0.52±0.21 and 0.66 ± 0.20 cm 3 for PAK7, MAP3K7 and CK2a, respectively. Volumes decreased to 0.23 ± 0.11, 0.22 ± 0.19 and 0.51±0.14 cm 3 after injections of PAK7/MAP3K7, PAK7/CK2a and MAP3K7/CK2a siRNAs, respectively. Finally, treatment with the triple combination PAK7/ MAP3K7/CK2a reduced the tumoral volume to 0.22±0.11 cm 3 . Survival kinase mRNA expression was checked by semiquantitative RT-PCR (Figure 6a ) and quantitative RT-PCR in tumors removed from mice ( Figure 6b ). We observed a strong decrease of mRNA expression in tumors removed from mice injected with their specific OMe-siRNAs (diminution of 45, 77 and 45% for PAK7, MAP3K7 and CK2a, respectively). We also checked caspase-3 activity in the tumors by immunohistochemistry on tumor sections. Caspase-3 activity was strongly induced in tumors removed from mice treated with single siRNAs (2.0-fold for MAP3K7), and dual combinations (2.3-fold for MAP3K7/CK2a), and was maximal in mice treated with all three siRNAs (3.2-fold) (Figure 6c ). It is noteworthy that whatever the number of kinases simultaneously inhibited (1, 2 or 3) the total amount of OMe-siRNA remained the same (30 mg per injection). This means that mice received 10 mg of each OMe-siRNA when the three kinases were to be inhibited.
Discussion
Our main aim is to develop new therapeutic strategies for pancreatic cancer because the only drugs presently Combining kinase inhibitors in pancreatic cancer V Giroux et al available improve patients' survival by a few weeks, at the best. Pancreatic adenocarcinoma differs from most other cancers in its absence of response to conventional anticancer strategies 5 because of its particular resistance to the induction of apoptosis. Therefore, rather than trying to fine-tune such therapeutic approaches, we chose to explore possible strategies based on new concepts. Our hypothesis was that inhibition of specific kinases might impair pancreatic cancer progression. This idea is actually not new as several kinase inhibitors are available to treat some cancers 11, 12 but the strategy developed to select the appropriate kinase(s) is, to our knowledge, original in the context of pancreatic cancer: All kinases from the human kinome were individually inhibited with siRNAs in pancreatic cancer cell cultures and those whose inhibition induced significant apoptosis were identified. Interestingly, simultaneous inhibition of two or more kinases potentiated apoptosis and similar experiments on several pancreatic cell lines led to similar results. Such a strategy has the advantage of being systematic, without a priori opinion on the involvement of a given kinase. It has the drawback of showing unexpected kinases, some of them poorly described or only known by their gene, and for which, obviously, no chemical inhibitor is available.
The demonstration that inhibition of kinases belonging to a restricted panel of 52 molecules altered pancreatic cancer development in vitro was encouraging in view of a new therapeutic strategy. The next step towards a proof of concept was to look whether increased apoptosis observed in vitro would translate in vivo into altered tumor Combining kinase inhibitors in pancreatic cancer V Giroux et al development. The best mouse model of pancreatic cancer presently available is the KrasG12D model. 13 Unfortunately, this model is not adapted to our study because kinases to be targeted were selected in human cells and there is no guarantee that the mouse counterparts of these kinases play the same role in mouse pancreatic cancer. We had no choice but to use a xenotransplant model already validated in our laboratory 8 in spite of its limitations, the most important of them being that it does not allow assessment of the effects of the injected siRNAs on normal pancreas and on other tissues because they are directed at human kinases. When injected in the pancreas of nude mice, MiaPaCa2 cells grow and form large tumors within 3 weeks. The question was whether inhibition of appropriate kinases, chosen in the panel established in vitro, would impair tumor growth in mice. However, the important observation that simultaneous inhibition of two kinases resulted in increased efficacy in vitro, and its potential therapeutic interest, led us to consider monitoring a similar setting in vivo in parallel with single-kinase inhibition. To choose the best candidates, we started from the 10 kinases whose inhibition had resulted in vitro in the highest induction of apoptosis 7 and assessed on two pancreatic cancer cell lines which couples of kinases would be most efficient. PAK7, MAP3K7 and CK2a, the three kinases whose dual inhibition induced highest apoptosis (more than threefold increase), were selected for further studies ( Figure 1 ).
As control, we compared the influences of their single, dual or triple inhibition on apoptosis and cell viability in two pancreatic cancer cell lines, MiaPaCa2 and BxPC3 (Figure 2) . Similar results were obtained in the two cell lines. Simultaneous inhibition of two kinases increased significantly the apoptosis, but concomitant inhibition of the third one only provided a small increment, as clearly evidenced by flow cytometry data ( Figure 2 ). Data on cell survival (Figure 2 ) led to similar conclusions.
We also wanted to assess the pancreatic specificity of the induction of apoptosis by the inhibition of the three kinases. As shown in Figure 3 , none of the 10 nonpancreatic cell lines that we tested showed any increase in spontaneous apoptosis after inhibition of the selected kinases. Although these findings do not allow prejudicing the situation in vivo, they suggest some tissue specificity of the observed phenomenon.
In pancreatic cells, the three selected kinases are clearly involved in maintaining apoptosis. In fact, earlier reports show that they are implicated in cell survival. PAK7 can inhibit the induction of apoptosis by localizing to the mitochondria and by phosphorylating the BAD protein, thus blocking BAD translocation to the mitochondria. Combining kinase inhibitors in pancreatic cancer V Giroux et al PAK7 can phosphorylate BAD directly on serine-112 and indirectly on serine-136 through AKT activation. The blockade of PAK7 relocalization to the mitochondria inhibits its antiapoptotic properties. 15 TGF-b is a pluripotent regulatory polypeptide, which plays a role in differentiation, proliferation and tissue morphogenesis. 16 Protein kinase MAP3K7, also known as TAK1 (TGF-bactivated kinase 1), is one of the downstream mediators of the receptors for TGF-b.
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MAP3K7 with its activator TAB1 (TAK1-binding protein 1) can activate NF-kB by an NIK (NF-kBinducing kinase)-independent mechanism, 18 but with a functional interaction with IKK (IkB kinase) a and IKKb. 19 This activation of NF-kB has been implicated in liver tumor formation. 20 However, several members of the IAP (inhibitors of apoptosis) family, such as XIAP, NAIP and ML-IAP, activate JNK1 survival pathway through interaction with MAP3K7 and its activator TAB1. 21 Whether MAP3K7 can be pro-apoptotic or promote survival in the same cell, depending on conditions, or whether the two opposite functions are tissue specific is unknown.
CK2 is a ubiquitous and constitutively active serine/ threonine protein kinase that is implicated, among many other functions, in apoptosis, 22 cell survival 23 and cell transformation. 24 The antiapoptotic action of CK2 occurs through the phosphorylation of BID, a pro-apoptotic member of the BCL-2 family, which becomes resistant to caspase cleavage 25 and the phosphorylation of ARC (apoptotic repressor with caspase recruitment domain) that blocks the activity of caspase 8. 26 Inhibitors of CK2 have been reported to trigger apoptosis and to increase the susceptibility of cancer cells to chemotherapeutic agents or apoptotic stimuli. [27] [28] [29] In fact, the survival function of CK2 in pancreatic cancer cells was already described. 30 Of the three selected kinases, CK2a is the only one for which a chemical inhibitor is commercially available. However, because of similarities between kinase active sites and lack of information on a vast majority of members of the human kinome, there is no guarantee that such an inhibitor will be specific and that the observed result will actually be attributable to CK2a inhibition only. By contrast, the use of appropriate antisense oligonucleotides or siRNAs allows specific inhibition. This is why we decided to use in vivo the same siRNA sequences as in vitro. However, to prevent rapid degradation by nucleases, five bases were O-methylated at both ends, as recommended by others. 9 We checked in vitro that O-Me modifications had not altered their efficacy (Figure 4 ) before proceeding to in vivo experiments. We monitored the efficacy of OMe protection in vivo with an OMe-siRNA to a non-relevant kinase (Mapk1). Inhibition was maximum 3 days after i.p. injection, then decreased, while remaining significant after 6 days (not shown). To ensure maximal inhibition of the three relevant kinases, OMe-siRNAs were injected every third day during the 21 days of the experiment. When inhibited alone, the three selected kinases did not induce significant reduction of tumor volume. However, simultaneous inhibition of MAP3K7 and CK2 reduced tumoral volume by 50%, maximum efficiency being obtained with PAK7 associated with MAP3K7 or CK2, which reduced tumoral volume by 75% ( Figure 5 ). Simultaneous inhibition of the three kinases did not improve that reduction, although caspase-3 activity seemed to be higher in that group than with other combinations. Tumor reduction is probably because of increased sensitivity to apoptosis. However, because siRNAs were administered only one day after cancer cells were injected into the pancreas, one cannot exclude the fact that tumor volume reduction was because of the impedance of proper engraftment by kinase inhibition. It is interesting to note ( Figure 6 ) that inhibition of kinase expression in the tumor, as judged by RT-PCR, was far from complete but remained in the 50% range, which might leave room for further reduction in cancer progression with strategies leading to more thorough kinase inhibition.
In conclusion, we have shown in a mouse xenograft model that inhibition of couples of specific kinases could considerably slow down pancreatic adenocarcinoma progression. The efficacy of modified siRNAs for in vivo inhibition is confirmed and could possibly be improved by refining the injection schedule and siRNA amounts. These results suggest that inhibitors of two of the three selected kinases, PAK7 and MAP3K7, might soon enter into clinical trial. Combining kinase inhibitors in pancreatic cancer V Giroux et al
